We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
-0.07%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$19.1B
AUM Growth
-$4.04B
Cap. Flow
-$3.24B
Cap. Flow %
-16.98%
Top 10 Hldgs %
50.33%
Holding
204
New
48
Increased
30
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
EA
Electronic Arts
EA
+$492M
2
AVGO icon
Broadcom
AVGO
+$292M
3
KKR icon
KKR & Co
KKR
+$280M
4
ROIV icon
Roivant Sciences
ROIV
+$248M
5
MA icon
Mastercard
MA
+$138M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$650M
2
CYBR
CyberArk
CYBR
+$470M
3
CRM icon
Salesforce
CRM
+$334M
4
NDAQ icon
Nasdaq
NDAQ
+$290M
5
RNAM
Avidity Biosciences
RNAM
+$233M

Sector Composition

Rank Sector Weight
1 Healthcare 46.53%
2 Communication Services 11.31%
3 Financials 11.23%
4 Technology 10.28%
5 Consumer Discretionary 4.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
101
Alkermes
ALKS
$8.23B
$735K ﹤0.01%
20,800
– –
ALVO icon
102
Alvotech
ALVO
$1.37B
$685K ﹤0.01%
199,675
– –
AXSM icon
103
Axsome Therapeutics
AXSM
$11.2B
$676K ﹤0.01%
4,000
– –
COGT icon
104
Cogent Biosciences
COGT
$6.58B
$654K ﹤0.01%
17,000
– –
ANNA
105
AleAnna Inc
ANNA
$113M
$650K ﹤0.01%
78,400
– –
ARQT icon
106
Arcutis Biotherapeutics
ARQT
$3.29B
$613K ﹤0.01%
26,000
– –
CELC icon
107
Celcuity
CELC
$4.49B
$457K ﹤0.01%
4,000
– –
LIVN icon
108
LivaNova
LIVN
$4.53B
$381K ﹤0.01%
6,000
– –
TERN
109
DELISTED
Terns Pharmaceuticals
TERN
$369K ﹤0.01%
7,000
-635,000
-99% -$26.1M
IONS icon
110
Ionis Pharmaceuticals
IONS
$9.51B
$360K ﹤0.01%
4,800
– –
TVTX icon
111
Travere Therapeutics
TVTX
$5.86B
$357K ﹤0.01%
12,000
– –
GMED icon
112
Globus Medical
GMED
$11.5B
$345K ﹤0.01%
4,000
– –
SRRK icon
113
Scholar Rock
SRRK
$6.4B
$344K ﹤0.01%
7,000
– –
ONC
114
BeOne Medicines Ltd
ONC
$39.3B
$327K ﹤0.01%
1,100
– –
WGS icon
115
GeneDx Holdings
WGS
$2.33B
$321K ﹤0.01%
5,000
-65,000
-93% -$5.93M
COR icon
116
Cencora
COR
$59.9B
$314K ﹤0.01%
1,000
– –
NUVL
117
DELISTED
Nuvalent
NUVL
$307K ﹤0.01%
3,000
– –
PGNY icon
118
Progyny
PGNY
$2.02B
$306K ﹤0.01%
18,000
– –
STOK icon
119
Stoke Therapeutics
STOK
$2.02B
$293K ﹤0.01%
9,000
– –
ERAS icon
120
Erasca
ERAS
$6.43B
$291K ﹤0.01%
+18,000
New +$213K
EHC icon
121
Encompass Health
EHC
$12.2B
$290K ﹤0.01%
3,000
-231,500
-99% -$23.7M
NKTR icon
122
Nektar Therapeutics
NKTR
$2.47B
$288K ﹤0.01%
+4,000
New +$228K
GKOS icon
123
Glaukos
GKOS
$10.9B
$280K ﹤0.01%
2,600
– –
MIRM icon
124
Mirum Pharmaceuticals
MIRM
$6.14B
$277K ﹤0.01%
3,000
– –
SBRA icon
125
Sabra Healthcare REIT
SBRA
$5.19B
$269K ﹤0.01%
14,000
– –
3 4
5
6 7

Similar funds

VARA
Value Aligned Research Advisors Princeton, New Jersey $20.7B AUM 292.88% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
NAM
Nissay Asset Management Tokyo, Japan $18.9B AUM 27.21% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return

Farallon Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Farallon Capital Management held 204 positions worth $19.1B, down 17% from $23.1B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Farallon Capital Management withdrew a net $3.24B in Q1 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was Exact Sciences, an estimated $650M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 41% a quarter earlier, followed by Communication Services and Financials.

Against the trend, Farallon Capital Management opened a new position in Dianthus Therapeutics worth $70.2M.

  • Farallon Capital Management's largest Q1 2026 buy was Dianthus Therapeutics: 836,000 shares worth $70.2M.
  • Farallon Capital Management added most to Electronic Arts in Q1 2026, an estimated $492M increase.
  • Farallon Capital Management's biggest Q1 2026 reduction was Wabtec, cutting an estimated $210M.
  • Farallon Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $650M.
  • Farallon Capital Management's ten largest holdings make up 50% of its $19.1B portfolio in Q1 2026.
  • Farallon Capital Management opened 48 new positions and closed 31 in Q1 2026.
  • Farallon Capital Management's portfolio value fell 17% quarter-over-quarter to $19.1B.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.